Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
  • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

• the present invention is directed to novel compounds, to a process for their preparation, their use and pharmaceutical compositions comprising the novel compounds.
• the novel compounds are useful in therapy, and in particular for the treatment of pain.
• the ⁇ receptor has been identified as having a role in many bodily functions such as circulatory and pain systems. Ligands for the ⁇ receptor may therefore find potential use as analgesics, and/or as antihypertensive agents. Ligands for the ⁇ receptor have also been shown to possess immunomodulatory activities.
• the problem underlying the present invention was to find new analgesics having improved analgesic effects, but also with an improved side- effect profile over current ⁇ agonists, as well as having improved systemic efficacy.
• novel compounds according to the present invention are defined by the formula I
• R is selected from any one of
• each R phenyl ring and R heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents independently selected from straight and branched C]-Cg alkyl, NO2, CF3, C i -C ⁇ alkoxy, chloro, fluoro, bromo, and iodo.
• the substitutions on the phenyl ring and on the heteroaromatic ring may take place in any position on said ring systems.
• novel compounds according to the present invention are defined by the formula
• R is selected from any one of
• the preferred substituents are independently selected from any one of CF3, methyl, iodo, bromo, fluoro and chloro.
• novel compounds of the present invention are useful in therapy, especially for the treatment of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc. This list should however not be interpreted as exhaustive.
• Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti- tumour agents and anti viral agents.
• Compounds of the invention are useful in disease states where degeneration or dysfunction of opioid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds of the invention in diagnostic techniques and imaging applications such as positron emission tomography (PET).
• PET positron emission tomography
• Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety, urinary incontinence, various mental illnesses, cough, lung oedema, various gastro- intestinal disorders, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.
• Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care.
• Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids.
• a further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the formula I above, is administered to a patient in need of such treatment.
• a further aspect of the present invention is intermediates of the general formula II
• PG is a urethane protecting group such as Boc or CBZ, or a benzyl or substituted benzyl protecting group, such as 2,4-dimethoxybenzyl.
• novel compounds according to the present invention may be administered orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, inrracerebroventricularly and by injection into the joints.
• a preferred route of administration is orally, intravenously or intramuscularly.
• the dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level as the most appropriate for a particular patient.
• inert, pharmaceutically acceptable carriers can be either solid or liquid.
• Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
• a solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
• the carrier is a finely divided solid which is in a mixture with the finely divided active component.
• the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
• a low- melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.
• Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low- melting wax, cocoa butter, and the like. Salts include, but are not limited to, pharmaceutically acceptable salts.
• Examples of pharmaceutically acceptable salts within the scope of the present invention include: acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium acetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glucaptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabarnine, hydrobromide, hydrochloride, hydroxynaphthoate, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate/diphosphate, polygalacturonate, salicylate
• Preferred pharmaceutically acceptable salts are the hydrochJorides, sulfates and bitartrates.
• hydrochloride and sulfate salts are particularly preferred.
• composition is intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it.
• a carrier which is thus in association with it.
• cachets are included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
• Liquid from compositions include solutions, suspensions, and emulsions.
• Sterile water or water- propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration.
• Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.
• Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired.
• Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
• the pharmaceutical composition is in unit dosage form. In such fonn, the composition is divided into unit doses containing appropriate quantities of the active component.
• the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules.
• the unit dosage fonn can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
• Human 293 S cells expressing cloned human ⁇ , ⁇ , and K receptors and neomycin resistance were grown in suspension at 37°C and 5% CO 2 in shaker flasks containing calcium- free DMEM10% FBS, 5% BCS, 0.1% Pluronic F-68, and 600 ⁇ g/ml geneticin.
• mice and rat brains were weighed and rinsed in ice-cold PBS (containing 2.5mM EDTA, pH 7.4). The brains were homogenized with a polytron for 15 sec (mouse) or 30 sec (rat) in ice-cold lysis buffer (50mM Tris, pH 7.0, 2.5mM EDTA, with phenylmethylsulfonyl fluoride, added just prior use to 0.5MmM from a 0.5M stock in DMSO:ethanol).
• ice-cold PBS containing 2.5mM EDTA, pH 7.4
• the brains were homogenized with a polytron for 15 sec (mouse) or 30 sec (rat) in ice-cold lysis buffer (50mM Tris, pH 7.0, 2.5mM EDTA, with phenylmethylsulfonyl fluoride, added just prior use to 0.5MmM from a 0.5M stock in DMSO:ethanol).
• Cells were pelleted and resuspended in lysis buffer (50 mM Tris, pH 7.0, 2.5 mM EDTA, with PMSF added just prior to use to 0.1 mM from a 0.1 M stock in ethanol), incubated on ice for 15 min, then homogenized with a polytron for 30 sec. The suspension was spun at 1000 g (max) for 10 min at 4 °C. The supernatant was saved on ice and the pellets resuspended and spun as before. The supernatants from both spins were combined and spun at 46,000 g (max) for 30 min. The pellets were resuspended in cold Tris buffer (50 mM Tris/Cl, pH 7.0) and spun again.
• lysis buffer 50 mM Tris, pH 7.0, 2.5 mM EDTA, with PMSF added just prior to use to 0.1 mM from a 0.1 M stock in ethanol
• Membranes were thawed at 37 °C, cooled on ice, passed 3 times through a 25-gauge needle, and diluted into binding buffer (50 mM Tris, 3 mM MgCfe, 1 mg ml BSA (Sigma A-7888), pH 7.4, which was stored at 4°C after filtration through a 0.22 m filter, and to which had been freshly added 5 ⁇ g/ml aprotinin, 10 ⁇ M bestatin, 10 ⁇ M diprotin A, no DTT). Aliquots of 100 ⁇ l were added to iced 12x75 mm polypropylene tubes containing 100 ⁇ l of the appropriate radioligand and 100 ⁇ l of test compound at various concentrations.
• binding buffer 50 mM Tris, 3 mM MgCfe, 1 mg ml BSA (Sigma A-7888), pH 7.4
• binding buffer 50 mM Tris, 3 mM MgCfe, 1 mg ml BSA (Sigma A
• Total (TB) and nonspecific (NS) .binding were detemiined in the absence and presence of 10 ⁇ M naloxone respectively.
• the tubes were vortexed and incubated at 25°C for 60-75 min, after which time the contents are rapidly vacuum- filtered and washed with about 12 ml tube iced wash buffer (50 mM Tris, pH 7.0, 3 mM MgCt) through GF/B filters (Whatman) presoaked for at least 2h in 0.1% polyethyleneimine.
• the radioactivity (dpm) retained on the filters was measured with a beta counter after soaking the filters for at least 12h in minivials containing 6-7 ml scintillation fluid.
• the filtration is over 96-place PEL soaked unifilters, which were washed with 3 x 1 ml wash buffer, and dried in an oven at 55°C for 2h.
• the filter plates were counted in a TopCount (Packard) after adding 50 ⁇ l MS -20 scintillation fluid well.
• the agonist activity of the compounds is measured by deterrriining the degree to which the compounds receptor complex activates the binding of GTP to G-proteins to which the receptors are coupled.
• GTP[ ⁇ ] 35 S is combined with test compounds and membranes from HEK-293S cells expressing the cloned human opioid receptors or from homogenised rat and mouse brain. Agonists stimulate GTP[ ⁇ ] 35 S binding in these membranes.
• the EC 50 and E r>ax values of compounds are determined from dose-response curves. Right shifts of the dose response curve by the delta antagonist naltrindole are performed to verify that agonist activity is mediated through delta receptors.
• the specific binding (SB) was calculated as TB-NS, and the SB in the presence of various test compounds was expressed as percentage of control SB.
• Values of IC50 and Hill coefficient (nj-i) for ligands in displacing specifically bound radioligand were calculated from logit plots or curve fitting programs such as Ligand, GrapliPad Prism, SigmaPlot, or ReceptorFit.
• Values of K j were calculated from the Cheng- Prussoff equation.
• Mean ⁇ S.E.M. values of IC50, K, and n ⁇ were reported for ligands tested in at least three displacement curves. Biological data are tabulated on the following pages in Table 1.
• Table 1 Biological data.
• Radioligand Kg values were dete ⁇ nined by perfoirning the binding assays on cell membranes with the appropriate radioligands at concentrations ranging from 0.2 to 5 times the estimated K ⁇ (up to 10 times if amounts of radioligand required are feasible).
• radioligand binding was expressed as pmole/mg membrane protein. Values of Kg and B max from individual experiments were obtained from nonlinear fits of specifically bound (B) vs. nM free (F) radioligand from individual according to a one- site model.
• Rats were placed in Plexiglas cages on top of a wire mesh bottom which allowed access to the paw, and were left to habituate for 10- 15 min. The area tested was the mid-plantar left hind paw, avoiding the less sensitive foot pads. The paw was touched with a series of 8 Von Frey hairs with logarithmically incremental stiffness (0.41, 0.69, 1.20, 2.04, 3.63, 5.50, 8.51, and 15.14 grams; Stoelting, 111, USA).
• the von Frey hair was applied from underneath the mesh floor perpendicular to the plantar surface with sufficient force to cause a slight buckling against the paw, 5 and held for approximately 6-8 seconds. A positive response was noted if the paw was sharply withdrawn. Flinching immediately upon removal of the hair was also considered a positive response. Ambulation was considered an ambiguous response, and in such cases the stimulus was repeated.
• the animals were tested on postoperative day 1 for the FCA-treated group.
• the 50%) l o withdrawal threshold was determined using the up-down method of Dixon (1980). Testing was started with the 2.04 g hair, in the middle of the series. Stimuli were always presented in a consecutive way, whether ascending or descending. In the absence of a paw withdrawal response to the initially selected hair, a stronger stimulus was presented; in the event of paw withdrawal, the next weaker stimulus was chosen.
• Optimal threshold calculation by this method requires 6 responses 15 in the immediate vicinity of the 50% threshold, and counting of these 6 responses began when the first change in response occurred, e.g. the threshold was first crossed.
• Rats were injected (subcutaneously, intraperitoneally, intravenously or orally) with a test substance prior to von Frey testing, the time between administration of test compound and the von Frey test varied depending upon the nature of the test compound.
• Acetic acid will bring abdominal contractions when administered intraperitoneally in mice. These will then extend their body in a typical pattern. When analgesic drugs are administered, this described movement is less frequently observed and the drug selected as a potential good candidate.
• a complete and typical Writhing reflex is considered only when the following elements are l o present: the animal is not in movement; the lower back is slightly depressed; the plantar aspect of both paws is observable.
• compounds of the present invention demonstrate significant inhibition of writhing responses after oral dosing of 1- 1 OO ⁇ mol/kg.
• Acetic acid 120 ⁇ L of Acetic Acid is added to 19.88 ml of distilled water in 15 order to obtain a final volume of 20 ml with a final concentration of 0.6% AcOH. The solution is then mixed (vortex) and ready for injection.
• the compound (drug) is administered orally, intraperitoneally (i.p.), subcutaneously (s.c.) or intravenously (i.v.)) at 10 ml/kg (considering the average mice body weight) 20, 30 or 40 minutes (according to the class of compound and its characteristics) prior to testing.
• Intraventricularly (i.c.v.) or intrathecally (it.) a volume of 5 ⁇ L is administered.
• the AcOH is administered intraperitoneally (i.p.) in two sites at 10 ml/kg (considering the 5 average mice body weight) immediately prior to testing.
• mice The animal (mouse) is observed for a period of 20 minutes and the number of occasions (Writhing reflex) noted and compiled at the end of the experiment. Mice are kept in individual "shoe box” cages with contact bedding. A total of 4 mice are usually observed at the same time: one control and three doses of drug.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Pain & Pain Management (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Publications (1)

Family

ID=20285553

Family Applications (1)

Country Status (19)

Cited By (16)

Families Citing this family (3)

Citations (2)

Family Cites Families (11)

• 2001
  • 2001-10-03 SE SE0103313A patent/SE0103313D0/xx unknown
• 2002
  • 2002-09-27 AR ARP020103670A patent/AR036649A1/es unknown
  • 2002-10-02 CA CA002460168A patent/CA2460168A1/en not_active Abandoned
  • 2002-10-02 IL IL16088902A patent/IL160889A0/xx unknown
  • 2002-10-02 HU HU0401915A patent/HUP0401915A2/hu unknown
  • 2002-10-02 JP JP2003532465A patent/JP2005505583A/ja not_active Abandoned
  • 2002-10-02 MX MXPA04003056A patent/MXPA04003056A/es unknown
  • 2002-10-02 CN CNA028195825A patent/CN1692100A/zh active Pending
  • 2002-10-02 BR BR0212959-0A patent/BR0212959A/pt not_active Application Discontinuation
  • 2002-10-02 PL PL02368804A patent/PL368804A1/xx not_active Application Discontinuation
  • 2002-10-02 KR KR10-2004-7004780A patent/KR20040039469A/ko not_active Withdrawn
  • 2002-10-02 RU RU2004107854/04A patent/RU2004107854A/ru not_active Application Discontinuation
  • 2002-10-02 US US10/491,263 patent/US7205317B2/en not_active Expired - Fee Related
  • 2002-10-02 EP EP02775640A patent/EP1440060A1/en not_active Withdrawn
  • 2002-10-02 WO PCT/SE2002/001804 patent/WO2003029215A1/en not_active Ceased
• 2004
  • 2004-03-30 ZA ZA200402514A patent/ZA200402514B/xx unknown
  • 2004-03-31 CO CO04030712A patent/CO5580822A2/es not_active Application Discontinuation
  • 2004-03-31 IS IS7203A patent/IS7203A/is unknown
  • 2004-04-27 NO NO20041964A patent/NO20041964L/no not_active Application Discontinuation

Patent Citations (2)

Also Published As

Similar Documents

Legal Events